Drugs / Intanza
last change Aug 2018 re-read 2 minutes ago

Intanza

Vaccine

Developed for
influenza
Investigated by
Sanofi Pasteur, a Sanofi Company · Brenda Coleman · The University of Hong Kong · University of Alberta · University of Lausanne Hospitals

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Withdrawn EU (EMA) Intanza 2018-08-03 europa.eu
Approved EU (EMA) Intanza 2009-02-24 europa.eu

Trials 5 · a red edge is where a trial was stopped

20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 22 trials
Phase 2 NCT02960815 Nov 2016 → Jun 2017 University of Lausanne Hospitals Completed No outcome recorded
Phase 2 NCT00776438 Sep 2007 → Feb 2009 influenza Sanofi Pasteur, a Sanofi Company Completed No outcome recorded
Phase 42 trials
Phase 4 NCT01967368 Oct 2013 → May 2014 influenza The University of Hong Kong Unknown No outcome recorded
Phase 4 NCT01665807 Sep → Dec 2012 influenza Brenda Coleman Completed No outcome recorded
Phase not applicable1 trial
NCT01180699 Oct 2010 → Aug 2012 University of Alberta Completed No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT01368796 Comparator Jul → Dec 2011 University of British Columbia Completed No outcome recorded
Phase 4 NCT01224613 Comparator Nov 2010 → Jan 2011 influenza Dalhousie University Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as Intanza Intanza® 9 μg (Sanofi Pasteur), a trivalent split-virion vaccine administered by intradermal (ID) injection” PMID 25483667 2014
6

NCT01224613

NCT01180699

NCT01368796

NCT01665807

NCT02960815

NCT01967368

Modality Vaccine “standard influenza vaccineNCT01180699
Route Other “It is given into the skin over the upper arm at a dose of 0.1 mL.” NCT01368796